Want to see AU:PCK full AI Analyst Report?
PCK Stock Chart & Stats
AU$0.29
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.29
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$1.05
Previous CloseN/A
Volume838.67K
Average Volume (3M)136.49K
Market Cap
AU$22.99M
Enterprise ValueAU$21.59
Total Cash (Recent Filing)AU$5.99M
Total Debt (Recent Filing)AU$4.25M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding209,007,310
10 Day Avg. Volume79,907
30 Day Avg. Volume136,491
Financial Highlights & Ratios
PEG Ratio1.77
Price to Book (P/B)-15.11
Price to Sales (P/S)5.78
P/FCF Ratio-2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth of about 45% in FY2026, following solid prior growth, indicates expanding adoption of the platform. If sustained, this scaling can broaden the enterprise customer base and improve operating leverage, creating a stronger foundation for future profitability.
Gross Margin ImprovementThe increase in gross margin from roughly 30% to 71% suggests materially better unit economics and a greater share of revenue retained after direct costs. Sustaining this improvement would strengthen the platform’s ability to absorb operating expenses as revenue expands.
Recurring Digital Health ModelA licensing model built around recurring software fees can support revenue visibility when organisations renew and expand deployments across facilities or users. PainChek’s focus on assessing people unable to reliably self-report also addresses a defined clinical and aged-care need.
Bears Say
Persistent UnprofitabilityDeeply negative operating results and a net margin near -239% show that current revenue is still far below the cost base. Without a clear path to breakeven, continued growth may not translate into earnings, limiting financial resilience over the coming periods.
Heavy Cash BurnPersistent negative operating and free cash flow means the business is not currently self-funding its operations or expansion. The worsening cash outflow increases reliance on capital raises or new financing, which can constrain strategic flexibility and add execution pressure.
Stressed Balance SheetNegative equity combined with newly added debt materially reduces financial flexibility and increases leverage risk while losses continue. This capital structure leaves less capacity to absorb setbacks and makes external funding more important for sustaining operations.
PainChek Ltd News
PCK FAQ
What was PainChek Ltd’s price range in the past 12 months?
PainChek Ltd lowest share price was AU$0.09 and its highest was AU$1.05 in the past 12 months.
What is PainChek Ltd’s market cap?
PainChek Ltd’s market cap is AU$22.99M.
When is PainChek Ltd’s upcoming earnings report date?
PainChek Ltd’s upcoming earnings report date is Mar 03, 2027 which is in 163 days.
How were PainChek Ltd’s earnings last quarter?
PainChek Ltd released its earnings results on Aug 27, 2026. The company reported -AU$0.02 earnings per share for the quarter.
Is PainChek Ltd overvalued?
According to Wall Street analysts PainChek Ltd’s price is currently Overvalued.
Does PainChek Ltd pay dividends?
PainChek Ltd does not currently pay dividends.
What is PainChek Ltd’s EPS estimate?
PainChek Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainChek Ltd have?
PainChek Ltd has 209,007,310 shares outstanding.
What happened to PainChek Ltd’s price movement after its last earnings report?
PainChek Ltd reported an EPS of -AU$0.02 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PainChek Ltd?
Currently, no hedge funds are holding shares in AU:PCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PainChek Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PCK Sentiment 94%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
254.84%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PainChek Ltd
PainChek Limited specializes in the creation and commercialization of mobile medical applications designed for individual pain assessment. Their core product, PainChek, employs smartphone and tablet cameras to record video, which is then analyzed in real-time by facial recognition software to detect the presence of pain. This technology is particularly beneficial for patients suffering from dementia. The company, which operates from its headquarters in Sydney, Australia, rebranded as PainChek Limited in January 2018, having previously been known as ePAT Technologies Ltd.
Technical Analysis
Cogstate Ltd
―
Oneview Healthcare Chess Depository Interests repr 1
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
InteliCare Holdings Limited
―